JOHN P. BUCCI

University of Texas Southwestern Medical Center, Dallas, TX, United States

Are you JOHN P. BUCCI?

Claim your profile

Publications (2)8.75 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: ObjectiveTo develop effect sizes for 3 mood stabilizers-lithium, divalproex sodium, and carbamazepine-for the acute-phase treatment of bipolar I or II disorder, mixed or manic episode, in children and adolescents aged 8 to 18 years.MethodForty-two outpatients with a mean age of 11.4 years (20 with bipolar I disorder and 22 with bipolar II disorder) were randomly assigned to 6 weeks of open treatment with either lithium, divalproex sodium, or carbamazepine. The primary efficacy measures were the weekly Clinical Global Impression Improvement scores and the Young Mania Rating Scale (Y-MRS).ResultsUsing a ≥50% change from baseline to exit in the Y-MRS scores to define response, the effect size was 1.63 for divalproex sodium, 1.06 for lithium, and 1.00 for carbamazepine. Using this same response measure with the intent-to-treat sample, the response rates were as follows: sodium divalproex, 53%; lithium, 38%; and carbamazepine, 38% (χ22 = 0.85, p = .60). All 3 mood stabilizers were well tolerated, and no serious adverse effects were seen.ConclusionsDivalproex sodium, lithium, and carbamazepine all showed a large effect size in the open treatment of children and adolescents with bipolar I or II disorder in a mixed or manic episode.
    Journal of the American Academy of Child & Adolescent Psychiatry 07/2000; · 6.97 Impact Factor
  • R A Kowatch, J P Bucci
    [Show abstract] [Hide abstract]
    ABSTRACT: This article provides pediatricians and other clinicians who treat children and adolescents with a working knowledge of mood stabilizers and their potential uses in children and adolescents with mood and behavior disorders. Mood stabilizers are ubiquitous agents that are often effective in the treatment of children and adolescents with bipolar disorders or conduct disorders and mentally retarded patients with aggressive behavior. The authors' also discuss mechanisms of action, pharmacokinetics, dosing, drug interactions, and potential uses. Following these medication details, specific information concerning the diagnosis and treatment of several child and adolescent mood and behavior disorders, and in which treatment with mood stabilizers may be helpful, is presented.
    Pediatric Clinics of North America 11/1998; 45(5):1173-86, ix-x. · 1.78 Impact Factor